IL-17

Dr. John Cush Tweet
@RheumNow
52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. Only IL‐6i & JAKi had https://t.co/wqogmfeAru
Dr. John Cush Tweet
@RheumNow
Meta-analysis 24 studies (3015 hidradenitis suppurativa pts) taking IL-17 inhibitor, IBD adverse events were rare, w/ no difference in IBD risk betw IL-17i & PBO (0.23% vs 0 of 2572 vs 1066 pts respectively) thru wk 16. The reported assocn of IL-17 inhibitors w/ IBD risk is https://t.co/kDwR5Fc1zI
Dr. John Cush Tweet
@RheumNow
High BMI decreases the odds for MDA in PsA, esp w/ TNFi Rx (but not Inflx, IL-17i, IL-12/23i, IL-23i, JAKi). Longitudinal PsA cohort 1291 pts (mean BMI 29); Higher BMI independently assoc w/ signif. lower odds for MDA (OR 0.97), also female, age, smoking, FM & Xray damage. https://t.co/zAJ8Pmk1HY
Dr. John Cush Tweet
@RheumNow
Secukinumab in Polymyalgia Rheumatica PMR is a common disorder of the elderly that responds well to GC, but is plagued by an inability to wean off of GCs. The NEJM has published the results of the REPLENISH trial demonstrating that secukinumab (an interleukin-17A inhibitor) is https://t.co/ijkHKC7IWJ
Dr. John Cush Tweet
@RheumNow
Spyre Therapeutics topline results of its anti-TL1A Ab (SPY072) in RA (n 133) sub-study: Phase 2 SKYWAY 12wk trial showed 2 doses SPY072 were signif better vs PBO for ACR20 (63% & 58% vs 43%), ACR50 (31% &38% vs 19%), DAS28-CRP reductions (-1.5 & -1.9 vs -1.3). TL1A inhib are https://t.co/S6gapB21uq
Dr. John Cush Tweet
@RheumNow
Prolonged exposure to targeted Rx in #SpA not assoc w/ increased cancer risk. French claims study 56,591 SpA pts- 1,224 CA (1,029 solid, 116 Heme). TNFi, IL17i, IL12/23i, IL23i, JAKi Exposure >6 vs ≤6 mos assoc w/ lower CA (HR 0.86; 0.75-0.99); signif for Heme (HR 0.65), not https://t.co/rHAa0CkAjT
Dr. John Cush Tweet
@RheumNow
MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG

Recent Blogs

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do! 
Read Post

Best of 2022: Toss of a Coin - How do You Choose PsA Medication?

M. Elaine Husni, MD, MPH
Coin toss
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they? 
Read Post

2021 GRAPPA Recommendations - Looking Back, Looking Forward

Artie Kavanaugh, MD
reflections,ripple
With the recent publication of the third iteration of the GRAPPA Psoriatic Arthritis (PsA) treatment recommendations, it seems to be an auspicious time to reflect on some key considerations that arose during the development of the recommendations, as well as to look towards what the future may hold.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • EULAR 2021 - Day2c 00:37:25
  • EULAR 2021 - Day2b 00:35:57

Topic Videos
×